TLSIHIGH SIGNALFINANCIAL10-K

TLSI shows substantially higher revenue growth alongside meaningful improvement in operating cash flow, but continues to operate at a loss with deteriorating equity position.

The company appears to be in a rapid growth phase with revenue expanding substantially, yet remains unprofitable with widening net losses and increasingly negative stockholders' equity of -$33.9M. The notable improvement in operating cash flow performance suggests better working capital management despite continued losses.

Comparing 2026-03-05 vs 2025-04-15View on EDGAR →
FINANCIAL ANALYSIS

TLSI demonstrated strong top-line growth with revenue expanding substantially while gross profit grew proportionally, indicating maintained margins. The company's financial position shows mixed signals - current assets increased meaningfully to $32.2M and operating cash flow improved considerably, but net losses widened and stockholders' equity became more deeply negative. Total liabilities grew to $69.2M, reflecting the company's continued reliance on external financing to fund operations during this growth phase.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+56%
$20.7M→$32.2M

Current assets grew 56% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
+55.9%
-$40.8M→-$18.0M

Operating cash flow surged 55.9% — exceptional cash generation, highest quality earnings signal.

Revenue
P&L
+53.4%
$29.4M→$45.2M

Strong top-line growth of 53.4% — accelerating demand or successful expansion into new markets.

Gross Profit
P&L
+50.8%
$25.3M→$38.2M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Assets
Balance Sheet
+47.4%
$24.0M→$35.3M

Asset base grew 47.4% — expansion through organic growth, acquisitions, or capital deployment.

Total Liabilities
Balance Sheet
+38.8%
$49.9M→$69.2M

Liabilities grew 38.8% — significant increase in debt or obligations, assess impact on financial flexibility.

Stockholders Equity
Balance Sheet
-30.8%
-$25.9M→-$33.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Net Income
P&L
-30.6%
-$30.0M→-$39.2M

Net income declined 30.6% — review whether driven by operations, interest costs, or non-recurring items.

Accounts Receivable
Balance Sheet
+28.9%
$5.1M→$6.6M

Receivables grew 28.9% — monitor days sales outstanding for collection efficiency.

Operating Income
P&L
+25.5%
-$36.2M→-$26.9M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-04-15
ADDED
APPLICABLE ONLY TO CORPORATE ISSUERS: The registrant had 61,306,437 outstanding shares of common stock as of March 2, 2026.
Management's Discussion and Analysis of Financial Condition and Results of Operations 72 Item 7A.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosures 118 Item 9A.
We caution you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond our control.
Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements.
For a further discussion of these and other factors that could cause our future results, performance or transactions to differ significantly from those expressed in any forward-looking statement, please see the section titled Risk Factors in this Annual Report.
Except to the extent required by applicable law, we are under no obligation (and expressly disclaim any such obligation) to update or revise their forward-looking statements whether as a result of new information, future events or otherwise.
Background Many solid tumors, especially desmoplastic tumors like pancreatic ductal adenocarcinoma ("PDAC"), liver tumors and various other tumor types have high interstitial fluid pressure which creates a physical barrier preventing therapeutics from penetrating the tumor.
We have developed a platform approach to address the unique challenges of drug delivery to solid tumors with the goal of overcoming the primary barriers described above that limit therapeutic delivery and inhibits treatment success.
PEDD TriNav- Device Business with Potential for Growth: Our delivery method, Pressure-Enabled Drug Delivery ( PEDD ), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies.
REMOVED
APPLICABLE ONLY TO CORPORATE ISSUERS: The registrant had outstanding 32,272,462 shares of common stock as of March 31, 2025.
Management's Discussion and Analysis of Financial Condition and Results of Operations 77 Item 7A.
Changes in and Disagreements w ith Accountants on Accounting and Financial Disclosures 128 Item 9A.
You should not place undue reliance on these forward-looking statements.
In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject.
RISK FACTOR SUMMARY Below is a summary of material factors that make an investment in our securities speculative or risky.
Importantly, this summary does not address all of the risks and uncertainties that we face.
Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found in the more detailed discussion in Item 1A in this Annual Report, and the below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties.
You should carefully consider the risks and uncertainties described herein as part of your evaluation of an investment in our securities: We have a limited operating history, have incurred significant losses since our inception and anticipate incurring increasing expenses and continuing losses for the foreseeable future.
Our need for additional capital raises substantial doubt about our ability to continue as a going concern.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →